Valid for Submission
C90.20 is a billable diagnosis code used to specify a medical diagnosis of extramedullary plasmacytoma not having achieved remission. The code C90.20 is valid during the fiscal year 2022 from October 01, 2021 through September 30, 2022 for the submission of HIPAA-covered transactions.
The ICD-10-CM code C90.20 might also be used to specify conditions or terms like extramedullary plasmacytoma, plasmacytoma or primary cutaneous plasmacytoma.
Tabular List of Diseases and Injuries
The Tabular List of Diseases and Injuries is a list of ICD-10 codes, organized "head to toe" into chapters and sections with coding notes and guidance for inclusions, exclusions, descriptions and more. The following references are applicable to the code C90.20:
Inclusion TermsInclusion Terms
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
- Extramedullary plasmacytoma with failed remission
- Extramedullary plasmacytoma NOS
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Extramedullary plasmacytoma
- Primary cutaneous plasmacytoma
Diagnostic Related Groups - MS-DRG Mapping
|MS-DRG||MS-DRG Title||MCD||Relative Weight|
|820||LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITH MCC||17||5.6873|
|821||LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITH CC||17||2.1551|
|822||LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITHOUT CC/MCC||17||1.2516|
The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.
Convert C90.20 to ICD-9 Code
The General Equivalency Mapping (GEM) crosswalk indicates an approximate mapping between the ICD-10 code C90.20 its ICD-9 equivalent. The approximate mapping means there is not an exact match between the ICD-10 code and the ICD-9 code and the mapped code is not a precise representation of the original code.
Information for Patients
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bones.
No one knows the exact causes of multiple myeloma, but it is more common in older people and African Americans. It can run in families. Common symptoms may include
- Bone pain, often in the back or ribs
- Fractures (broken bones)
- Weakness or fatigue
- Weight loss
- Frequent infections and fevers
- Feeling very thirsty
- Frequent urination
Doctors diagnose multiple myeloma using lab tests, imaging tests, and a bone marrow biopsy. Your treatment depends on how advanced the disease is and whether you have symptoms. If you have no symptoms, you may not need treatment right away. If you have symptoms, you may have chemotherapy, stem cell transplantation, radiation, or targeted therapy. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells.
NIH: National Cancer Institute
[Learn More in MedlinePlus]
Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®) Learn about plasma cell neoplasm (including multiple myeloma) risk factors, symptoms, tests to diagnose, factors affecting prognosis, staging, and treatment.
[Learn More in MedlinePlus]